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Abstract The hypothesis was tested that 9 kinase inhibitors with 
diverse specificities for protein kinase C (PKC), including stauro- 
sporine and four of its analogues, interfere differently with PKC 
derived from either the cytosolic or particulate fractions of MCF- 
7 breast carcinoma cells. GF 109203X inhibited the enzyme iden- 
tically in either preparation. CGP 41251 and calphostin C inhib- 
ited cytosolic PKC more effectively than membrane-derived PKC 
with ratios of ICso (cytosolic PKC) over IC50 (membrane-derived 
PKC) of 0.07 and 0.04, respectively. The other six agents inhib- 
ited membrane-derived PKC more potently than cytosolic en- 
zyme. Staurosporine and RO 31 8220 exhibited IC50 ratios of 
12.3 and 21.6, respectively. The results suggest that there are 
dramatic differences between kinase inhibitors in their divergent 
effects on cytosolic and membrane-derived PKC which should be 
borne in mind in the interpretation of their pharmacological prop- 
erties. 
but possess much better selectivity for PKC [7-10]. Two such 
PKC-specific analogues, UCN-01 and CGP 41251, have been 
shown to possess antineoplastic a tivity in human tumour mod- 
els grown in rodents [9, 11]. In most investigations of the ability 
of compounds to inhibit PKC, cytosolic enzyme preparations 
have been used. In the light of the fact that it is predominantly 
PKC in the membrane which is of functional importance, we 
tested the hypothesis that kinase inhibitors display different 
potencies against membrane-derived as compared to cytosolic 
enzyme. To that end nine well-characterised PKC inhibitors, 
including staurosporine and four analogues, were investigated 
with respect o their ability to inhibit PKC prepared from the 
cytosol or membrane of human-derived MCF-7 breast cancer 
cells. The susceptibility of these cells towards the growth-arrest- 
ing ability of PKC inhibitors has recently been described [12]. 
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1. Introduction 
Protein kinase C (PKC) is a family of enzymes which are 
pivotal constituents of signalling pathways and thus regulate 
cellular growth, differentiation and a variety of processes in- 
volved with homeostasis [1]. In its inactive state a major pro- 
portion of PKC can be recovered as a soluble enzyme in most 
cell types. However the activated apoenzyme is thought o be 
positioned at the surface of intracellular membranes to permit 
efficient phosphorylation of membrane proteins [2]. In most 
cells PKC activition elicits the rapid redistribution of enzyme 
from the cytosol to the membrane and nucleus [3]. Inhibitors 
of PKC have been frequently used as probes to clarify the role 
which the enzyme plays in regulating cell function [4]. They are 
also under consideration as potential therapeutic agents in the 
treatment of diseases uch as asthma, dermatological disorders, 
rheumatoid athritis, cancer and AIDS [5]. Many of the agents 
which possess PKC-inhibitory activity, like the indolocarbazole 
staurosporine, isolated from Streptomyces staurosporeus [6], 
inhibit a variety of kinases indiscriminately and thus lack selec- 
tivity for PKC. However during the last few years analogues 
of staurosporine have been synthesised which retain, at least in 
part, the high kinase-inhibitory potency of the parent molecule, 
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Abbreviations: IC50, concentration which inhibited enzyme activity by 
50%; PKC, protein kinase C; aPKC atypical PKC; cPKC, conventional 
PKC; nPKC, novel PKC; 
2. Materials and methods 
2.1. Chemicals' and reagents 
Calphostin C, H-7 and GF 109203X were purchased from Calbio- 
chem-Novabiochem Co. (Nottingham, UK). UCN-01, RO 31 8220, 
CGP 41251, NPC 15-437 and miltefosine were gifts from Kyowa 
Hakko Kogyo Co. (Tokyo, Japan), Roche Research Centre (Welwyn 
Garden City, UK), Ciba Geigy (Basel, Switzerland), Nova Pharmaceu- 
tical Co. (Baltimore, MD, USA) and Asta Pharma (Frankfurt, Ger- 
many), respectively. All other chemicals and reagents including stauro- 
sporine were obtained from Sigma Chemical Co. (Poole, UK). Cell 
culture medium, and serum were purchased from Gibco BRL (Paisley, 
UK). Stock solutions of drugs were prepared in DMSO, except in the 
case ofNPC 15-437 which was dissolved in water, and stored at -20 ° C. 
Monoclonal antibodies against PKC-c~ and -e were purchased from 
Tissue Culture Services Ltd. (Botolph Claydon, UK) and Affiniti Ltd, 
(Nottingham, UK), respectively, and a polyclonal antibody against 
PKC-( was obtained from Gibco BRL (Paisley, UK). 
2.2. Cell growth and preparation of cellular fractions 
MCF-7 breast carcinoma cells from the European Collection of An- 
imal Cell Cultures (Salisbury, UK) were maintained routinely in an 
atmosphere of 02 : CO2 (95 : 5) in minimum essential medium (Eagles 
modified) with fetal calf serum (10%), pyruvate (1 mM), L-glutamine 
(2 mM), non-essential amino acids, penicillin (100 iu/ml) and strepto- 
mycin (100 ¢tg/ml). Cells were cultured in petri dishes (140 mm diame- 
ter) until they reached confluency. Cell cytosol was prepared according 
to Dale et al. [13]. The particulate (membrane) fraction was obtained 
from cells which had been exposed to phorbol dibutyrate (10/IM) for 
30 min prior to fractionation to achieve redistribution f PKC to the 
membrane. Several methods of membrane preparation were evaluated. 
The procedure ultimately chosen was essentially that described by Greif 
et al. [14], except hat the membrane pellet, once collected, was sus- 
pended by sonication and solubilised in buffer containing Brij 58 
(0.1%), as described by Rush et al. [15]. The suspension was left on ice 
for 1 h and recentrifuged. The resultant supernatant was investigated. 
In comparison to the other protocols tested this method was optimal 
in that it furnished a preparation which (i) allowed endogenous inhib- 
itors to be diluted out effectively, (ii) contained only low 'non-specific' 
radioactivity (10% of total), which means activity not associated with 
PKC-specific substrate, and (iii) retained PKC activity associated with 
the membrane. Membrane-derived PKC activity was between 185 and 
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198% of that seen in cells which had not been exposed to phorbol 
dibutyrate. 
2.3. PKC activity assay 
Cytosolic and membrane preparations were diluted by a factor of 
between 5 and 20, depending on preparation, with H8 buffer (20 mM 
Tris-HC1, 2 mM of both EDTA and EGTA, 6 mM fl-mercaptoethanol, 
2 pg/ml of both leupeptin and aprotinin, at pH 7.5) until endogenous 
inhibitors, which would have masked effects of the drugs under inves- 
tigation, were diluted out. Aliquots (25 pl) of the diluted cytosol or 
particulate fraction were placed in microplate wells and PKC activity 
was determined using a kit from Amersham lntemational plc (Aylesbury, 
UK). PKC was activated with 12-O-tetradecanoylphorbol-13- acetate 
and the incorporation of the 7-phosphate moiety of [32p]ATP into a 
PKC-specific peptide was measured. Radioactivity was counted on a 
Packard Tricarb 1500 scintillation counter. Drugs were added to the 
incubate and degree of inhibition of PKC activity was expressed as 
percentage of drug-free control. Whereas cytosolic PKC did not phos- 
phorylate the PKC-specific substrate significantly in the absence of 
TPA, Ca2+and phospholipid, membrane-derived enzyme xhibited al- 
ready 85% of maximal achievable activity in the absence of TPA, and 
90% without added Ca 2÷ and phospholipid. 
2.4. Western blot analysis 
Immunoblot analysis was performed as described previously [16]. 
The amount of protein loaded per lane was 20 pg. Detection was by 
enhanced chemiluminescence generated by oxidation of luminol in the 
presence of hydrogen peroxide using an ECL kit from Amersham 
International. 
3. Results 
In order to compare the effect of kinase inhibitors on PKC 
activity associated with cellular cytosol or membrane, cytosol 
was obtained from naive cells and membrane fraction from cells 
in which PKC had been redistributed to the membrane by 
exposure to phorbol dibutyrate for 30 min. Immunoblot analy- 
sis showed that cytosolic PKC consisted mainly of PKC-e and 
-(with little PKC-~, which afforded a faint band not detectable 
by densitometry or on a photograph. PKC-( was also found 
in the membrane of untreated cells (Fig. 1). On treatment with 
phorbol dibutyrate nPKC-e underwent translocation to the 
particulate fraction, whereas the phorbol ester-insensitive 
aPKC-~" did not (Fig. 1). Fig. 2 shows that there were remark- 
able differences between the PKC preparations in their suscep- 
tibility towards the inhibitory potential of the nine compounds 
tested. Staurosporine was the most and miltefosine the least 
potent PKC inhibitor. Only one compound, GF 109203X, fur- 
nished the same IC50 value irrespective ofenzyme source (Table 
1). UCN-01, H-7, NPC 15437 and miltefosine were all 
stronger inhibitors of membrane-derived than of cytosolic 
PKC. For these agents differences in IC50 values amounted to 
between 2.4- to 5.5-fold (Table 1). The most dramatic discrep- 
ancies in inhibitory potency between cytosolic and membrane- 
derived PKC were seen with RO 31 8220, staurosporine, CGP 
41251 and calphostin C. RO 31 8220 and staurosporine inhib- 
ited membrane-derived enzyme 22 and 12 times, respectively, 
more effectively than cytosolic PKC, as judged by differences 
in IC50 values. In contrast, CGP 41521 and calphostin C inhib- 
ited cytosolic PKC 14 and 28 times, respectively, better than 
membrane-derived enzyme. 
4. Discussion 
The nine kinase inhibitors tested in this study are widely used 
as probes for the involvement ofPKC in cellular processes, and 
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Fig. 1. Effect of exposure of MCF-7 cells to phorbol dibutyrate (PDBu) 
(10/tM) on localisation of PKC-e and -(. Cytosolic (C) and particulate 
fractions (P) were prepared and analysed by Western blotting as de- 
scribed in section 2. Cells did not immunoreact with antibodies against 
PKC-fl, -7, -~, or -0, and cytosol reacted only faintly with a monoclonal 
anti-PKC-c~ antibody (results not shown). 
two of them, UCN-01 and CGP 41251 are experimental antitu- 
mour agents [9,11]. The results presented above show, for the 
first time, that all but one differ markedly in their ability to 
modulate PKC activity depending on whether the enzyme was 
derived from the cytosol or the membrane subsequent to its 
redistribution there. PKC in the membrane is arguably more 
important as a functional kinase than cytosolic enzyme. The 
results presented above imply that potent kinase modulators 
can display as much as a twentyfold ifference in inhibitory 
efficacy between cytosolic and membrane-derived PKC. This 
discrepancy may explain the frequently observed lack of corre- 
lation between pharmacological response and PKC inhibition. 
Particularly noteworthy is the increased inhibitory potency of 
RO 31 8220 and staurosporine against membrane-derived as 
compared to cytosolic enzyme, and the markedly decreased 
ability of CGP 41251 and calphostin C to inhibit membrane- 
derived in comparison tocytosolic PKC. Calphostin C does not 
only inhibit PKC, but also inactivates it irreversibly in a light- 
dependent fashion [17]. Gopalakrishna etal. showed that cal- 
phostin C exhibited higher potency against membrane-derived 
than cytosolic PKC in experiments in which cells were treated 
with the drug preceeding preparation of cellular subfractions 
and subsequent determination of enzyme activity [18]. This 
finding contrasts tarkly with the result described above ac- 
cording to which calphostin C, when incubated with cellular 
subfractions rather than intact cells, inhibited cytosolic PKC 
much more effectively than membrane-derived enzyme. The 
disparity suggests that intact cells are able to provide cofactors 
and/or to catalyse calphostin C metabolism necessary for max- 
imal inactivation of the enzyme, whereas isolated homogenate 
fractions lack this ability. Few investigations have addressed 
differences insusceptibility owards pharmacological inhibitors 
between cytosolic and membrane-derived PKC. The ether lipid 
l-octadecyl-2-O-methyl-sn-glycerol-3-phosphocholine, an ex- 
perimental ntitumour drug, was found to inhibit PKC when 
enzyme was derived from cellular cytosol, but paradoxically, to
behave like a PKC activator in preparations in which the en- 
zyme was obtained after its redistribution to the membrane [19]. 
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Fig. 2. Inhibition of cytosolic (open squares) and membrane-associated PKC (closed circles) from MCF-7 cells by staurosporine, UCN-01, RO 31 
8220, GF 109203X, CGP 41251, NPC 15-437, H-7, miltefosine and calphostin C. In preliminary experiments a suitable concentration range was 
established for each compound and 3 appropriately spaced concentrations were chosen. The graphs how the result of one experiment representative 
of three. 
In the light of this finding and the results described above for 
calphostin C, CGP 41251, staurosporine and RO 31 8220, it is 
conceivable that the selectivity of some kinase inhibitors for 
PKC, when it is derived from the membrane, over other kinases 
is very different from that based on values reported in the 
literature which were derived using cytosolic PKC. 
Table 1 
Inhibition of cytosolic and membrane PKC from MCF-7 cells by kinase 
inhibitors 
Compound IC50" (tiM) 
Cytosolic PKC Membrane PKC Ratio b 
Staurosporine 0.0163 +0.0045 0.0013 + 0.0001 12.3 
UCN-01 0.0178 + 0.0020 0.0032 + 0.0009 5.5 
GF 109203X 0.021 + 0.004 0.021 _+ 0.004 1.0 
CGP 41251 0.044 + 0.006 0.61 + 0.14 0.07 
RO 31 8220 0.048 + 0.006 0.0022 + 0.0002 21.6 
Calphostin C 1.09 + 0.18 30.0 _+ 6.2 0.04 
NPC 15-437 43.3 _+ 6.9 17.9 +_ 2.8 2.4 
H-7 54.3 _+ 7.5 15.2 + 0.6 3.5 
Miltefosine 577 + 29 184 + 17 3.1 
"Concentration at which enzyme activity is inhibited by 50%. Values are 
the mean + S.D. of 3 experiments. PKC was measured using a PKC- 
specific peptide substrate as described in section 2. 
blCs0 (cytosolic PKC)/ICs0 (membrane-associated PKC). 
Six of the agents tudied here, H-7 [20], staurosporine [6] and 
its cogeners UCN-01 [7], RO 31 8220 [8], CGP 41251 [9] and 
GF  109203X [10], are thought to inhibit PKC at the catalytic 
site. Three of them, calphostin C [21], NPC 15-437 [22] and 
miltefosine [23] act at the regulatory domain of the enzyme. 
UCN-01, RO 31 8220, CGP 41251, GF  109203X, calphostin C
and NPC 15-437 possess specificity for PKC, whereas H-7, 
staurosporine and miltefosine are non-selective kinase inhib- 
itors. In the light of the results outlined above it is doubtful that 
the differences between the compounds are mechanistically 
linked to either PKC domain, at which the inhibitors interact 
with the enzyme, or degree of selectivity for PKC. 
The MCF-7 cells used in this study express only PKC-e and 
-5, apart form traces of PKC-c~ at the detection limit. Other 
PKC isoenzymes were not found in the cells [16]. On the as- 
sumption that there are no additional as yet undefined phorbol 
ester-responsive PKC isoenzymes in MCF-7 cells, the activity 
measured by the assay used in this study was due to PKC-e in 
both the cytosolic and membrane preparations, in the latter 
after efficient redistribution by phorbol dibutyrate. In the ab- 
sence of altered isoenzyme content, which difference between 
the two preparations might explain their differential sensitivity 
towards the kinase inhibitors? It is probably the fact that unlike 
cytosolic enzyme, membrane-derived PKC on isolation from 
phorbol ester-pretreated cells exists in a 'physiologically acti- 
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vated state'. It has been pointed out that membrane-derived 
PKC differs considerably in activation properties from cy- 
tosolic enzyme, even after the lipid environment has been sim- 
ilarly reconstituted in both [2]. Membrane-derived PKC seems 
to maintain its characteristic shape and properties in spite of 
the fact that its isolation procedure requires the use of detergent 
disrupting the intrinsic interactions between the protein and its 
lipid microenviroment. 
It could be argued that the observations outlined above are 
applicable only to the particular cocktail and relative levels of 
PKC isoenzymes expressed in the MCF-7 cells used in this 
study. The results of a preliminary experiment conducted with 
human-derived A549 lung carcinoma cells render this possibil- 
ity unlikely. These cells express predominantly PKC-c~, to- 
gether with PKC-( and -e at lower levels [16]. The differences 
in potency of PKC inhibitors for cytosolic and membrane- 
derived PKC in these cells were very similar to those shown in 
Fig. 2 (results not shown). 
Staurosporine at 10 -9 M and its analogues UCN-01, RO 31 
8220 and GF 109203X in the 10 -7 to 10 .6 M range cause the 
translocation f PKC-e from the cytosol to the membrane and 
nucleus of A549 cells [12]. In contrast, CGP 41251 does not 
possess this property. It is intriguing that among the stauro- 
sporine analogues tudied here CGP 41251 is the only one 
which inhibited membrane-derived PKC less potently than cy- 
tosolic enzyme. The two phenomena, bility to induce PKC-e 
translocation o  the one hand and high affinity for membrane 
PKC on the other, might be mechanistically related in this class 
of compound. 
In summary, the results presented here show that kinase 
inhibitors can interfere with cytosolic and membrane-derived 
PKC to a markedly different degree. The high potency of stau- 
rosporine and RO 31 8220, and the weak efficacy of CGP 41251 
and calphostin C against membrane-derived PKC should 
clearly be considered in the interpretation f their pharmacol- 
ogical effects. 
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